Cure Rare Disease Inc
Woodbridge, CT ·EIN 82-2473513 ·Grant funding profile from IRS 990 filings
Who funds Cure Rare Disease Inc?
Cure Rare Disease Inc is funded by 32 grantmakers, led by MKW of TEXAS ($458K), Mirabito Philanthropy Inc ($135K), Muscular Dystrophy Association ($80K). In total, IRS Form 990 filings record $1.1M in grants to Cure Rare Disease Inc between 2019–2024.
Showing top 25 of 32 funders by total given.
What grants has Cure Rare Disease Inc received?
Individual grants from IRS Form 990 filings, newest first
| Year | Funder | Purpose | Amount |
|---|---|---|---|
| 2024 | MKW of TEXAS | Contributions | $458,300 |
| 2024 | Muscular Dystrophy Association | ADVOCACY | $50,000 |
| 2024 | Mirabito Philanthropy Inc | GENERAL USE | $10,000 |
| 2024 | Two or More Foundation | General & Unrestricted | $10,000 |
| 2024 | C Cowles Community Trust | UNRESTRICTED GIFT | $2,500 |
| 2024 | George & Stephanie Suddock Foundation | GENERAL SUPPORT | $1,882 |
| 2024 | Chubb Charitable Foundation | Matching Gifts | $1,000 |
| 2024 | Joe & Cindy Goldberg Family | GENERAL USE | $500 |
| 2024 | The Cigna Group Foundation | GENERAL OPERATING PURPOSE | $50 |
| 2024 | American Express Foundation | GENERAL SUPPORT | $10 |
| 2023 | Muscular Dystrophy Association | ADVOCACY | $30,000 |
| 2023 | Mirabito Philanthropy Inc | GENERAL USE | $25,000 |
| 2023 | The Riedman Foundation | General & Unrestricted | $25,000 |
| 2023 | Charities Aid Foundation America | CHARITABLE DONATION | $20,291 |
| 2023 | Fairfield County's Community Foundation | FOR GENERAL SUPPORT. | $20,000 |
| 2023 | The Neuromuscular Disease Foundation | Research | $10,000 |
| 2023 | Two or More Foundation | General & Unrestricted | $10,000 |
| 2023 | Morgan Stanley Global Impact Funding Trust Inc | UNRESTRICTED GENERAL SUPPORT | $10,000 |
| 2023 | The Hometown Foundation Inc | TO ASSIST IN THE CHARTIABLE PURPOSE OF THE ORGANIZATION. | $10,000 |
| 2023 | The Wieczorek Family Foundation | TO BRIDGE THE GAP BETWEEN RESEARCHERS AND A CURE. | $10,000 |
| 2023 | The Antonacci Family Foundation | GENERAL SUPPORT | $5,300 |
| 2023 | Envision Healthcare Charitable Fund | General Support | $5,000 |
| 2023 | Butzel Long Charitable Trust | CURE RARE DISEASE IS A 501 (C) (3) NON-PROFIT BIOTECHNOLOGY COMPANY BASED IN BOSTON, MASSAHUSETTS THAT IS WORKING TO CREATE NOVEL THERAPEUTICS USING GENE THERAPY TO TREAT PEOPLE IMPACTED BY RARE DISEASES. | $1,500 |
| 2023 | Dr John S Levy Foundation Trust | TO OR FOR THE USE BY THE CHARITABLE ORGANIZATION FOR CHARITABLE PURPOSES. | $1,000 |
| 2023 | Joe & Cindy Goldberg Family | GENERAL USE | $1,000 |
| 2023 | Bristol-myers Squibb Foundation Inc | EMPLOYEE GIVING PROGRAM | $700 |
| 2023 | Bristol-myers Squibb Foundation Inc | EMPLOYEE GIVING PROGRAM | $600 |
| 2023 | Bristol-myers Squibb Foundation Inc | EMPLOYEE GIVING PROGRAM | $500 |
| 2023 | Chubb Charitable Foundation | Matching Gifts | $500 |
| 2023 | Bristol-myers Squibb Foundation Inc | EMPLOYEE GIVING PROGRAM | $500 |
Showing 30 most recent of 78 recorded grants.
Frequently Asked Questions
Who funds Cure Rare Disease Inc?
Cure Rare Disease Inc is funded by 32 grantmakers, led by MKW of TEXAS ($458K), Mirabito Philanthropy Inc ($135K), Muscular Dystrophy Association ($80K). In total, IRS Form 990 filings record $1.1M in grants to Cure Rare Disease Inc between 2019–2024.
Who is Cure Rare Disease Inc's largest funder?
MKW of TEXAS is the largest recorded funder of Cure Rare Disease Inc, with $458K across 1 grant (2024).
How much grant funding has Cure Rare Disease Inc received?
IRS 990 filings record $1.1M in grants to Cure Rare Disease Inc across 78 grants from 32 funders between 2019–2024. Filings are published on a delay, so recent grants may not appear yet.
Looking for funders like Cure Rare Disease Inc's?
Grantable's AI matches your organization against 200,000+ grantmakers — including every funder on this page — using their real giving history.
Grant data is drawn from IRS Form 990 filings via Grantable's GrantGraph™. Filings are published on a delay; recent grants may not appear yet.